ClinicalTrials.gg
Status unknownNCT06091878INDAGA-UKUpdated Aug 9, 2024

Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers

An observational study in Salivary Gland Cancer, sponsored by Royal Marsden NHS Foundation Trust. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Royal Marsden NHS Foundation Trust · Observational

The sponsor has not verified this record recently (last verified Aug 2024), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

The INDAGA-UK trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. We will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. Subject and sample identification will occur over a 12-month period. Samples and data will be analysed over the next 12 months prior to study end.

02

Conditions studied

  • Salivary Gland Cancer
03

In context

Salivary Gland Neoplasms

159 studies on the registry are indexed under Salivary Gland Neoplasms; 29 are open to participants now.

This study's planned enrollment of 250 is above the median of 169 across 21 observational studies indexed under Salivary Gland Neoplasms.

Browse Salivary Gland Neoplasms studies →

Lead sponsor

Royal Marsden NHS Foundation Trust is the lead sponsor of 272 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Participants with a salivary gland cancer diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged over 18
  2. Histological diagnosis of salivary gland cancer (SGCs)
  3. Availability of archival tissue (acceptable after 2013 up to present)
  4. Ability to give informed consent (if applicable)* for retrieving histological specimen and preform molecular analysis *De-identified archival tissue from deceased patients will be collected as part of the study once REC approval is in place, if the patient was alive when the samples were taken and they are not part of the NHS opt out scheme.

Exclusion criteria

Exclusion Criteria:

  1. Different H\&N cancer of other histology
  2. Thyroid cancers
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Other: Observation

Interventions

  • OtherObservation

    Observational study, no intervention

06

What researchers measure

Primary outcomes

  1. • Description of the molecular and genomic profile of locally advanced and recurrent-metastatic SGCs.

    • Description of the molecular and genomic profile of locally advanced and recurrent-metastatic SGCs.

    Time frame: Time Frame: Through study completion, expected duration of 10 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091878
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Sep 1, 2024 (estimated)
Primary completion
Jan 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Aug 9, 2024

Study contacts

Pablo Jimenez
Contact
pablo.jimenez@rmh.nhs.uk
02073528171
Sarah Burton
Contact
sarah.burton@rmh.nhs.uk
02073528171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion